You are here

Methods for improving the properties of antibody-drug conjugates

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA171492-01A1
Agency Tracking Number: R43CA171492
Amount: $215,740.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
863 MITTEN RD, STE 102
BURLINGAME, CA 94010-1311
United States
DUNS: 9000820
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DAVID JACKSON
 (650) 231-4320
 djackson@igenica.com
Business Contact
 JOHN CELEBI
Phone: (650) 231-4320
Email: jcelebi@igenica.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Antibody drug conjugates (ADCs), a rapidly growing class of targeted therapeutics, represent a promising new approach toward improving both the selectivity and the cytotoxic activity of cancer drugs. Although several ADCs have demonstrated recent clinical success, the utility of most ADCs currently in development is limited by cumbersome synthetic processes, insufficient anti-tumor activity, and unpredictable toxicity. We believe that these drawbacks can be addressed byimprovements in both linker technology and the cytotoxic drugs used to construct the ADCs. Our broad long-term goal is to develop novel ADCs with improved potency, homogeneity and stability over existing targeted therapeutics. Igenica has developed two proprietary technology platforms that provide a complementary function-oriented screening strategy to systematically identify novel tumor associated antigen targets and antigen-specific monoclonal antibodies for constructing ADCs with improved pharmacolo

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government